Amrit Raj
Stories by Amrit Raj
India: IHH Healthcare, TPG-Manipal submit fresh bids for Fortis acquisition
TPG-Manipal, which had earlier agreed to pay Rs 180 per share, may have lowered its bid.
India: Reliance Industries mulls IPO of telecom unit Jio in next 2-3 years
Reliance Jio’s short-term plan is to engage with customers, and continue to add subscribers.
India: UltraTech to acquire Century Textiles’ cement business in all-stock deal
The enterprise value of Century’s cement business is pegged at Rs 8,561 crore and UltraTech will absorb debt of Rs 3,000 crore.
India: Bidding war for Fortis intensifies as Malaysia’s IHH, Munjal-Burmans revise offer
Malaysia’s IHH Healthcare Bhd. on Tuesday revised its offer to Rs175 per share from its earlier offer Rs160 per share, which it made on 24 April.
Sunil Munjal, Burman family question Fortis bid deadline extension
The statement also questioned an exclusive right that the TPG Capital-Manipal Health Enterprises Ltd combine has to revise its offer within five days
Last-minute binding bid from Malaysia’s IHH heats up race for Fortis
This makes IHH the third entity after TPG-backed Manipal Hospital and an unnamed entity comprising Delhi-based businessman Sunil Munjal and some membe
Ranjan Pai tops India’s most successful entrepreneurs list with Fortis-Manipal deal
On Tuesday, the board of Manipal Education approved the merger of its hospital assets with that of Fortis Healthcare.
India’s Fortis sells hospital business to Manipal, TPG Capital
The deal catapults TPG-backed Manipal Health to pole position among India’s largest hospital chains, with a combined annual revenue of Rs5,400 crore
India: Hiranandani to invest $538.3m in oil and gas business in diversification bid
Led by Darshan Hiranandani, H-Energy expects to start commercial operation of its first LNG terminal at Jaigarh in Maharashtra by October.
Lafarge-controlled ACC, Ambuja Cements pause merger citing constraints on mining legalities
The merger, which would have potentially created India’s second largest cement maker, still remains the “ultimate objective”, the companies said
